Seelos Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SEEL research report →
About the company
Seelos Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to the discovery, development, and eventual commercialization of innovative therapies. These treatments primarily target central nervous system (CNS), respiratory, and various other medical conditions.
- CEO
- Raj Mehra
- IPO
- 1999
- Employees
- 8
- HQ
- New York City, NY, US
Price Chart
- Market Cap
- $214.97K
- P/E
- -0.05
- P/S
- 0.10
- P/B
- -0.05
- EV/EBITDA
- -0.30
- Div Yield
- 0.00%
- Gross Margin
- -1267.09%
- Op Margin
- -1838.36%
- Net Margin
- -1719.56%
- ROE
- 171.72%
- ROIC
- 210.04%
- Revenue
- $2.20M · 0.00%
- Net Income
- $-37,882,000 · 50.25%
- EPS
- $-7.73 · 64.01%
- Op Income
- $-40,499,000
- FCF YoY
- 61.18%
- 52W High
- $0.37
- 52W Low
- $0.37
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.94
- Avg Volume
- 0
Get TickerSpark's AI analysis on SEEL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 29, 24 | Golembiewski Michael Joseph | other | 417 |
| Jan 12, 24 | Mehra Raj | other | 70,383 |
| Jan 12, 24 | Golembiewski Michael Joseph | other | 24,537 |
| Jan 4, 24 | Pascoe Richard W | other | 1,666 |
| Jan 4, 24 | DALESANDRO MARGARET | other | 1,666 |
| Jan 4, 24 | Lian Brian | other | 1,666 |
| Jan 4, 24 | O'Connor Daniel J. | other | 1,666 |
| Nov 30, 23 | Golembiewski Michael Joseph | buy | 83,000 |
| Dec 1, 23 | Mehra Raj | buy | 75,757 |
| Dec 1, 23 | Mehra Raj | buy | 75,757 |
Our SEEL coverage
Recent articles, reports, and earnings notes.
No research on SEEL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SEEL report →Similar companies
Peers in the same neighborhood.